TR08A
An Innovative ODS column with amazing peak responses

A general purpose ODS phase for a wide-range of compound polarities
Amazing peak responses for basic compounds in formic acid mobile phase
Superior steric selectivity and molecular recognition for similar structures
Low pressure - high performance 3µm particles
Spherical porous silica / 3um particle / 12nm pore / C18 phase / pH 2-10 / MW up to 10 kDa / USP L1

A Novel Surface Modification Technology
Polar End-Capping Technology

1OH

32

OCH2CHCH2NHCH

CH3CH31

propranolol
CH32

CHOCH2CH2 NCH3diphenhydramine
O3CHCH2CH2NCH3CH3doxepine

CONVENTIONAL C18CONVENTIONAL C180.1% HCOOH in acetonitrile/water
Conventional ODS columns, including hybrid-silica type columns, require extensive end-capping
in order to decrease residual silanols, which may negatively affect peak shape for basic
compounds. Traditionally, this end-capping process has used methyl silane compounds whichhave a mild hydrophobic interaction. Viewing this interaction in terms of reversed-phase mode, thesurface of the stationary phase presents two very different kinds of hydrophobic structures,
octadecyl ligands(C18) and the methyl end-capping. These different hydrophobicities may provide
an inconsistent response against a solutes interaction with the stationary phase, resulting in poor
peak shape and reduced plate counts.
Instead of relying on traditional end-capping with trimethyl silane (TMS) compounds, we havesucceeded to develop a revolutionary surface modification technology using alcohol structures,
which has been adapted to our brand new Cadenza CX-C18. This means that electrostaticinteraction from the polar end-capped surface and hydrophobic interaction from the C18 ligand
will localize the polarity of the surface and increase the recognition power of a complex
compounds hydrophobic/hydrophilic structure. Therefore, Cadenza CX-C18 will have analternative selectivity for certain compounds and possibly improved peak shape compared toconventional end-capped ODS columns.
Imtakt USA (info@imtaktusa.com)
North America

Imtakt Corp./JAPAN (info@imtakt.com)
Other Countries

TR08AE-RJ27

Superior peak shape and molecular recognition
A novel polar end-capping technology for Cadenza CX-C18, vastly different from traditional methods, will
improve peak response due to a dramatic reduction in residual surface silanols, and also improve
molecular recognition.

The unique polar end-capping structure on
Cadenza CX-C18 provides significantly
different retention and separation
characteristics from traditionally endcapped C18 columns.
In terms of hydrophobicity, it is similar tomore traditional material like our UK-C18,
due to a similar ODS ligand density.
Electrostatic interaction is much less than
Unison UK-C18, but slightly higher thanCadenza CD-C18.
Steric selectivity is the largest among
comparable ODS phases, due to theunique polar end-capping structure. Highsteric selectivity may be useful for isomer
separation, especially for compounds thatare not resolved well using traditional ODS
columns.

Basic Interactions
Electrostatic Interaction

Hydrophobicity

Steric Selectivity

Cadenza CW-C18

BRAND-Z

BRAND-X

Cadenza CD-C18

Cadenza CL-C18

Cadenza CD-C18

Cadenza CL-C18

Cadenza CW-C18

Cadenza CW-C18

Cadenza CD-C18

BRAND-L

BRAND-B

BRAND-L

BRAND-Z

BRAND-L

BRAND-Z

BRAND-B

Unison UK-C18

Unison UK-C18
BRAND-X

Unison UK-C18
BRAND-X

Cadenza CL-C18
0.00.10.20.30.4

0.00.5water / methanol = 70 / 30
OH3CNON

CH30.5

BRAND-B
1.0

1.5

2.00.0water / methanol = 20 / 80

OH

CH2CH2CH2CH2CH30.5

1.0

1.5

2.0

One example is the structural isomers ofparaben. Here you can see that traditional
ODS columns, relying predominantly onhydrophobic mechanisms, struggle withthis isomer separation. Cadenza CX-C18
shows better results than our previous
products and other company's columns,
such as Brand-XB C18 column,
highlighting the usefulness of its highsteric selectivity.

water / methanol = 20 / 80

CH2CH2CH2CH3NNCH3caffeine

phenolamylbenzene

butylbenzene

Steric Selectivity
uracil(2/1) =1.4

triphenylene o-terphenyl

Isomers /Analogs

BRAND-XB C18Rs(4/3) = 1.9

1 methylparaben
2 ethylparaben
3 isopropylparaben
4 propylparaben
5 isobutylparaben
6 butylparaben

BRAND-XB C18 (3.5 µm)
125 6
o-terphenyl

triphenylene

150 x 3 mm
acetonitrile / water / acetic acid = 40 / 60 / 0.1
0.4 mL/min, 37°C, 260nm

150 x 3 mm
MeOH / water = 80 / 20
0.4 mL/min, 37°C
260nm
112341234562Rs(4/3) = 2.6(3µm)(2/1) = 2.2

13324456Rs(4/3) = 2.3
34(2/1) =1.4Rs(4/3) = 2.4

132052
1Cadenza CD-C18

4
101O

215N CCH3O

1

N-acetyl-4benzoquinone imine(2/1) = 1.62 HOH
N CCH3O

acetaminophen
101020 min

Comparing
selectivity
between CX-C18 and UKC18, you can see that elution
order was reversed for thesecompounds. This is likely dueto differences in the surface
polarity from the uniquepolar end-capping.

220 min

2978

Cadenza CX-C18 also benefits from having highmolecular structure recognition.
A planer triphenylene and bulky terphenyl are
well separated on CX-C18, due to the advantageof having a polar surface structure. It is worth
noting here that the differences between thesecompounds are not hydrophobic.
Therefore, CX-C18 may be effective to resolve
similar compounds where separation issues
predominate using traditional ODS columns.

1150 x 3 mm
water / ACN / HCOOH= 95 /5 /0.1
0.4 mL/min, 37°C, 260nm

0510

This is one example of how
CX-C18 may be effective forchanging
selectivity
compared to conventional
ODS columns.

15 min9822

Excellent peak shape for basic compounds under acidic conditions
It is common to use acidic mobile phases when analyzing basic compounds, but this often leads to peak tailing.
This is because the dissociated positive cation(s) on basic compounds may interact in an inconsistent way withresidual silanol anions. Cadenza CX-C18, which has a homogeneous surface due to a more complete coverage ofthese surface silanols, provides excellent peak shape for basic compounds under acidic conditions.

Basic Compounds (Acidic Mobile Phase)O

1

CHCH2CH2N

2doxepine

121CH3CH3N
CH2CH2 N

CH3C1(3µm)

NCl

CH3

CH2CH2 CH2N

imipramine

CH3H

32

chlorpheniramine

CH3CH3N

3
CHCH2CH2N

amitriptyline

3 4CH32CH3

H3C O

4N

dextromethorphan

CH3

CH2CHCH2N

CH3CH3trimipramine

O12510

COCH2CH2CH3HO(3µm)

150 x 3 mm
A: water / HCOOH = 100 / 0.1
B: ACN / HCOOH = 100 / 0.1
CX-C18 (20%B)
Brand-XB (38%B)
0.4 mL/min , 37°C, 260nm

4303BRAND-XB C18propylparaben
A: water / formic acid = 100 / 0.1
B: acetonitrile / formic acid = 100 / 0.1
5-95%B (0-15min)
0.4mL/min, 37°C, 280nm

BRAND-XB C18(3.5µm)

15min

05

1015 min972984

Tricyclic antidepresants tend to show peak tailingunder acidic conditions. Cadenza CX-C18 provides
excellent sharp peaks for these compounds.

Basic drug compounds are a primary ingredient of cold medicine. Cadenza CXC18 provides better peak shape, even under acidic conditions.

trans-doxepin

31cyclohexylamine[M+H]+ m/z 100.1

NH242O

21NH21-hexylamine[M+H]+ m/z 102.1

1-octylamine[M+H]+ m/z 130.1

3

CHCH2CH2N

1-octadecylamine[M+H]+ m/z 270.3

4

Conventional C18150 x 3 mm
A: water / formic acid = 100 / 0.1
B: acetonitrile / formic acid = 100 / 0.1
0-100%B (0-7min), 100%B (7-10min)
0.4 mL/min (7-8MPa), 37°C
2µL (10ug/mL, 0.1%HCOOH in 60%ACN)
ESI (positive)10250 x 3 mm
water / acetonitrile / formic acid= 88 /12 / 0.1
0.4 mL/min, 37°C
20µL (100ng/mL, 0.1%HCOOH)
ESI, positive

NH2324608 min
989

PowderedCoptis Rhizome 10mg
1% formic acid 1mL

3.0mixing(sonification, 10min)

N+O

berberine

2.0O

150 x 3 mm
A: water / formic acid = 100 / 0.1
B: acetonitrile / formic acid = 100 / 0.1
0-90%B (0-10 min)
0.4 mL/min (9 MPa), 37°C, 5 µL
ESI (positive)

1000-fold dilution
with 0.1% formic acid

1.0Injection Sample0.0012330 min

Ocentrifugation(12 krpm, 10 min)Supernatant

20Doxepin has both cis and trans isomeric
structures. Traditional columns struggle toseparate these isomers under acid conditions
using formic acid on LC-MS due to peak tailing.
Cadenza CX-C18 shows dramatically reduced
tailing under these conditions.

Oberberine
2.7ng[M]+ m/z 336.1

10cis-doxepin

980

Cadenza CX-C18 will respond better, not only for polar compounds, but alsohydrophobic amines under acidic conditions.
4.0(x10e6)[M+H]+ m/z 280.1

CH3doxepin

NH242CH345678910 min
993

3Berberine alkaloid in an herbal natural medicine
is well analysed on LC-MS using Cadenza CXC18 under acidic conditions

Compatibility for various compounds
Cadenza CX-C18 has the potential to analyze not only basic compounds but also a variety of acidic andneutral compounds with different selectivities.

Acidic Compounds
150 x 3 mm
A: 50mM ammonium formate
B: acetonitrile
25-95%B (0-10min)
0.4mL/min, 37°C, ELSD

1O OSONa

1150 x 3 mm
A: 50mM ammonium formate
B: acetonitrile
40-85%B (0-10min)
0.4 mL/min, 37°C
ESI (negative) 100pg

sodium heptylsulfonate
O OSONa

22sodium octylsulfonate

3131F FF FF F O

2O O
SO
ONa

Na+F FF F O O
SOHF FF F

PFBS
perfluorobutanesulfonic acid

23FF

OH

F FF FF FF F

PFOA
perfluorooctanoic acidsodium dodecylsulfate[M-H]- m/z 298.9

3[M-H]- m/z 412.9

PFOS
perfluorooctanesulfonic acid

[M-H]- m/z 498.9
0246

F FF FF FF F O O
SOHFF FF FF FF F

810 min
990Organo-fluoro compounds such as PFOS and PFOA are important in
resolving issues related to the environment.
Cadenza CX-C18 enables high sensitivity LC-MS analysis, using neutral
pH and ESI-Negative mode.
051015 min991

Cadenza CX-C18 enables separation of ionicdetergents. These compounds are challenging
because they have both hydrophobic chains
and anionic functionality. Hydrophobic alkyl
sulfate/sulfonate are well-retained andseparated on Cadenza CX-C18.

Peptide Selectivity
5

1. Angiotensin III (Human)[M+2H]2+ m/z 466.2
2. [Val5]- Angiotensin I (Bovine)[M+3H]3+ m/z 428.2

132

3. Angiotensin II (Human)[M+2H]2+ m/z 523.7

45

4. Angiotensin I (Human)[M+3H]3+ m/z 432.9

It is common to use formic acid mobile phases
for peptide LC-MS analysis.
1

Cadenza CX-C18 has a benefit, not only for basic
compounds, but also for peptides under acidic
conditions.

3

BRAND-XB C18
Cadenza CX-C18 has many opportunities toimprove peak shape and resolution for a wide
variety of compound analyses under formic acidand LC-MS conditions.

5. Angiotensin IV (Human)[M+2H]2+ m/z 388.2

0224468 min

150 x 3 mm
A: water / formic acid = 100 / 0.1
B: acetonitrile / formic acid = 100 / 0.1
CX-C18 (5-30%B in 15min)
Brand-XB (15-40%B in 15min)
0.4 mL/min, 37°C, ESI (positive)
988

PRODUCT INFORMATIONPRODUCT NAME

(3µm)
(5µm)

Micro/Nano and Metal-free columns are available.

COLUMN I.D.

COLUMN LENGTH

GUARD SYSTEM

1mm, 1.5mm, 2mm, 3mm
4.6mm, 6mm, 10mm
20mm(5µm), 28mm(5µm)

10mm, 20mm, 30mm, 50mm
75mm, 100mm, 150mm
250mm, 500mm(3µm)

Guard Holder
Cartridge Column

Pacings: 3µm 5µm; Pore: 12nm, Stationary phase: Octadecyl, Polar end-capping, Pressure: 250bar (HT:500bar, UP:1000bar) , USP L1

Imtakt USA (info@imtaktusa.com)
North America

Imtakt Corp./JAPAN (info@imtakt.com)
Other Countries